Keyphrases
SIK2
100%
SIK3
58%
Bleomycin-induced Lung Injury
50%
Thymic T Cell Development
50%
Fibrosis
50%
Nintedanib
28%
Bleomycin-induced Pulmonary Fibrosis
21%
SIK1
20%
Conditional Knockout
19%
Knock-in Mouse Model
19%
Lung Fibrosis
14%
Idiopathic Pulmonary Fibrosis
14%
Cell number
12%
CD-8
12%
Peripheral T Cells
12%
T Cell Development
12%
Single Positive
12%
Hematopoietic Cells
12%
Salt-inducible Kinase
12%
Developmental Phenotype
7%
Vascular Endothelial Growth Factor
7%
IC50
7%
Receptor Tyrosine Kinase
7%
Kinase Target
7%
Limited Treatment Options
7%
Histological Score
7%
Tyrosine Kinase Inhibitor
7%
Fibroblast Growth Factor Receptor 1 (FGFR1)
7%
Knock-in mutation
7%
Fatal Infection
7%
Putative Drug Targets
7%
Platelet-derived Growth factor-BB (PDGF-BB)
7%
Collagen Deposition
7%
Tyrosine Kinase
7%
Immune System
7%
Normal B Cells
6%
CD5 Positive
6%
Constitutive Knockout
6%
Neuronal Function
6%
Negative Selection
6%
TCRβ
6%
Control Function
6%
Adaptive Immunity
6%
Thymus
6%
Innate Immunity
6%
Combining Loss
6%
Apoptosis
6%
Thymocytes
6%
Double-positive Thymocytes
6%
Positive Selection
6%
Surface Expression
6%
TCR Complex
6%
B Cells
6%
Am(III)
6%
Metabolic Control
6%
Immunology and Microbiology
T Cell Development
50%
CD4
37%
T Cell
25%
Thymocyte
25%
CD8
25%
T Cell Receptor
25%
B Cell
25%
Transgene
25%
Innate Immune System
12%
Cell Surface
12%
Thymus
12%
Adaptive Immune System
12%
CD5
12%
Knockout Mouse
12%
Metabolic Regulation
12%
Pharmacology, Toxicology and Pharmaceutical Science
Fibrosis
50%
Phosphotransferase
50%
Bleomycin-Induced Lung Injury
50%
Table Salt
50%
Nintedanib
25%
Lung Fibrosis
12%
Bleomycin-Induced Pulmonary Fibrosis
12%
Protein Tyrosine Kinase
12%
Fibrosing Alveolitis
12%
Vasculotropin
6%
Protein Tyrosine Kinase Inhibitor
6%
Platelet Derived Growth Factor
6%
Fibroblast Growth Factor Receptor
6%
Disease
6%
Knockout Mouse
6%
Bleomycin
6%
IC50
6%